Precision Immunotherapy™
investors-relations
Home/Investor Relations/Press Releases
Investor Relations

Quick Links

Email Alerts

Email Address *
Mailing Lists *

 
Enter the code shown above.

Press Releases

2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005
11/29/2006 Opexa Therapeutics to Present at BMO Capital Markets Focus on Healthcare Conference
11/13/2006 Opexa Reports Third Quarter Financial Results
11/06/2022 Opexa Begins Dosing Patients in Phase IIb Trial of Tovaxin™ for Multiple Sclerosis
10/31/2006 Opexa Therapeutics to Present at Rodman & Renshaw Eighth Annual Healthcare Conference
10/23/2006 Opexa Therapeutics to Present at C.E. Unterberg, Towbin Life Sciences Investor Conference
09/18/2006 Opexa Commences Phase IIb Multiple Sclerosis Study; Reports Positive Phase I/II Data; Provides Update on Preclinical Progress
09/01/2022 Opexa Shares to Trade on NASDAQ Global Market
08/14/2006 Opexa Reports Second Quarter Financial Results
06/26/2006 Scientists at Opexa Therapeutics Generate Human Insulin-Producing Islet Clusters in Culture from Monocyte-Derived Stem Cells
06/19/2006 PharmaFrontiers Changes Name to Opexa Therapeutics; New Ticker Symbol is OPXA
06/16/2006 PharmaFrontiers Appoints Michael Richman to Board of Directors
06/06/2022 PharmaFrontiers to Present at Marcus Evans Conference, ``Facing Stem Cell Research Challenges''
05/15/2006 PharmaFrontiers Reports First Quarter 2006 Results
05/03/2022 PharmaFrontiers Names Lynne Hohlfeld Vice President of Finance
04/17/2006 PharmaFrontiers Appoints Gregory Bailey, M.D. and Scott Seaman, CPA, to Board of Directors
04/17/2006 PharmaFrontiers Completes $23 Million Financing to Advance Therapeutics; Plans Reverse Stock Split
04/13/2006 PharmaFrontiers to Present Data on Adult Human T-Cell Vaccination Technology at the Federation of Clinical Immunology Societies Annual Meeting
04/06/2022 PharmaFrontiers to Present at BIO 2006 Business Forum
03/31/2006 PharmaFrontiers Reports Year End 2005 Financial Results
03/28/2006 PharmaFrontiers to Present Data on Adult Human T-Cell and Stem Cell Technologies at the International Society for Cellular Therapy Annual Meeting
03/22/2006 PharmaFrontiers to Present Tovaxin(TM) Research at Consortium of Multiple Sclerosis Centers' Annual Meeting
02/23/2006 PharmaFrontiers Announces Financing Plans
01/17/2006 PharmaFrontiers Acquires Autologous T Cell Vaccine Rights for Rheumatoid Arthritis
© 2013 Opexa Therapeutics, Inc. All Rights Reserved.
Powered By Q4 Web Systems 4.1.3.41